Episode 30: A New Far-Out Trial: Welcome to Jupiter
The topic for our 30th episode is stolen from the headlines. We look at the much publicized Jupiter trial of C-Reactive Protein (CRP) and the use of a statin. We review the details, strengths and weakness of the trial. From there we look at related questions of risk assessment with CRP, reducing CRP and the uncertainty in the lipid hypothesis. We end by concluding that although trust in mechanisms and theories can lead to poor decisions they are generally less confusing than our podcasts.
Show Notes
1) Jupiter – statins, lipids and CRP
2) Knowing CRP doesn’t change estimation of cardiovascular risk
Arch Intern Med 2006;166:1368-73
3) Web site calculator that uses CRP
4) Ezetrol Study (reduces CRP but no other change)
N Engl J Med 2008;358:1431-43.
5) Mechanistic mistaken thinking Beta-blockers in CHF
Arch Intern Med 2002;162:641-8
Anti-oxidant studies
Atenolol for BP but not for outcomes
Listening to this episode is for premium podcast members only. If you already have a membership, login to your account. If you aren't yet a premium subscriber, sign up today!
